NCT01409148

Brief Summary

The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive monoclonal antibody to document the presence and distribution of amyloid deposits by PET/CT imaging in patients with AL amyloidosis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
38

participants targeted

Target at P50-P75 for phase_1

Timeline
Completed

Started Nov 2008

Typical duration for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2008

Completed
2.7 years until next milestone

First Submitted

Initial submission to the registry

July 28, 2011

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 4, 2011

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2012

Completed
Last Updated

October 11, 2012

Status Verified

August 1, 2011

Enrollment Period

3.3 years

First QC Date

July 28, 2011

Last Update Submit

October 10, 2012

Conditions

Keywords

RadioimmunoimagingAL AmyloidosisPET/CT

Outcome Measures

Primary Outcomes (1)

  • Radioimmunoimaging of AL amyloid deposits

    36 months

Secondary Outcomes (1)

  • Imaging of amyloid deposits as determined by PET/CT

    10-14 days

Study Arms (1)

I-124 Mu 11-1F4 sterile injection

OTHER

Single arm study

Biological: 124I-labeled monoclonal antibody Mu 11-1F4

Interventions

Single infusion of radiolabeled antibody: 2mCi (1 mg)

I-124 Mu 11-1F4 sterile injection

Eligibility Criteria

Age21 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Confirmed diagnosis of AL Amyloidosis

You may not qualify if:

  • New York Heart Association class IV
  • patient on renal dialysis
  • serum antibodies to mouse protein

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Tennessee Medical Center

Knoxville, Tennessee, 37920, United States

Location

Related Links

MeSH Terms

Conditions

Immunoglobulin Light-chain Amyloidosis

Condition Hierarchy (Ancestors)

Neoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasmsAmyloidosisProteostasis DeficienciesMetabolic DiseasesNutritional and Metabolic DiseasesLymphoproliferative DisordersImmunoproliferative DisordersImmune System DiseasesParaproteinemias

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Medicine

Study Record Dates

First Submitted

July 28, 2011

First Posted

August 4, 2011

Study Start

November 1, 2008

Primary Completion

March 1, 2012

Study Completion

March 1, 2012

Last Updated

October 11, 2012

Record last verified: 2011-08

Locations